In order for a tunable anti-VEGF therapy for the treatment of wet AMD to be successful, it is likely that free VEGF levels will need to be tightly regulated so that they reach a steady state concentration wherein CNV formation is prevented, but retinal atrophy is not accelerated. The gene discussed is VEGFA; the disease is Retinal atrophy.